HRMY - Harmony Biosciences subsidiary extends expiration of offer to acquire Zynerba
2023-09-27 09:20:33 ET
More on Harmony Biosciences, Zynerba Pharmaceuticals, etc.
- Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep
- Harmony Bio falls as Goldman Sachs cuts to Sell on revenue risks
- Harmony Bio expects FDA to reject citizen petition on sleep therapy
For further details see:
Harmony Biosciences subsidiary extends expiration of offer to acquire Zynerba